AbbVie and Genmab Advance Epcoritamab Trials for Lymphoma, Show Promising Results in Phase 3 Trials

AbbVie and Genmab are advancing trials of epcoritamab, a T-cell engaging bispecific antibody, which has shown promising results in a Phase 3 study for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial found improvements in progression-free survival and other key response metrics, although overall survival did not reach statistical significance. The companies plan to discuss the findings with global regulatory bodies and future studies are anticipated to explore the use of epcoritamab in combination with existing DLBCL therapies. AbbVie operates in the healthcare sector with a strong focus on immunology and oncology, and its financial metrics indicate a mixed performance with high valuation ratios and declining margins.